Vilobelimab
As of the edition of 20 October 2026, Vilobelimab is an antibody: marketed, first approved in 2025 (EU); acts on C5.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Antibody
- Brand name
- Gohibic
- First approved
- 13 January 2025 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- InflaRx
- Registered trials
- 10, 3 stopped early
- Disease areas
- Skin and connective tissue; Lungs and airways; Infections; Heart and blood vessels; Immune system; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Vilobelimab.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| C5 | Complement C5 | P01031 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 8 | 4 | 2 | 2 |
| Phase 3 | 2 | 1 | 0 | 1 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| InflaRx | Applicant and Lead sponsor of trials | 2016 to now |